| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 56,258 | 52,590 | 50,041 | 47,651 |
| Cost of goods sold excluding amortization | 2,954 | 2,736 | 3,521 | 2,551 |
| Research and development | 22,563 | 21,990 | 35,712 | 16,776 |
| Selling, general and administrative | 60,273 | 64,616 | 50,084 | 37,573 |
| Intangible asset amortization | 1,752 | 1,751 | 1,752 | 1,751 |
| Total operating expenses | 87,542 | 91,093 | 91,069 | 58,651 |
| Loss from operations | -31,284 | -38,503 | -41,028 | -11,000 |
| Other income, net | 2,894 | 3,616 | 3,660 | 4,756 |
| Loss before income taxes | -28,390 | -34,887 | -37,368 | -6,244 |
| Benefit for income taxes | -5,804 | -7,680 | -7,874 | -920 |
| Net loss | -22,586 | -27,207 | -29,494 | -5,324 |
| Basic (in dollars per share) | -0.38 | -0.46 | -0.5 | -0.09 |
| Basic (in shares) | 59,091,478 | 58,993,990 | 58,527,775 | 58,261,961 |
| Diluted (in dollars per share) | -0.38 | -0.46 | -0.5 | -0.09 |
| Diluted (in shares) | 59,091,478 | 58,993,990 | 58,527,775 | 58,261,961 |
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)